Highlights•ICIs have shifted the treatment paradigm to improve overall survival in advanced
SCLC.•The magnitude of immune-chemotherapy strategy is still modest. The …

Small cell lung cancer (SCLC) is a highly lethal subtype of lung cancer with a particularly
poor prognosis. For decades, the best available systemic therapy was platinum plus …

Small cell lung cancer (SCLC) was defined as a “recalcitrant cancer” because of its dismal
prognosis and lack of outcome improvements in the last 30 years. Immunotherapy with …

Despite decades of research, prognosis for SCLC patients remains poor, and treatment
options limited. SCLC is an immunogenic tumor with high somatic mutation rates due to …

Background Small cell lung cancer (SCLC) represents approximately 15% of lung cancers,
and approximately 70% are diagnosed as extensive‐stage SCLC (ES‐SCLC). Although ES …

Immune-checkpoint inhibitors (ICIs) are approved in the first-line and third-line settings for
patients with extensive-stage or relapsed small-cell lung cancer (SCLC), respectively. In the …

For many years the standard of care for small cell lung cancer (SCLC) has remained
unchanged. Despite decades of active research, current treatment options are limited and …

Small cell lung cancer (SCLC) represents about 13%–15% of all lung cancers. It has a
particularly unfavorable prognosis and in about 70% of cases occurs in the advanced stage …

Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Lung cancer is the second most common cancer in both sexes worldwide. Small‐cell lung
cancer (SCLC) is a form of neuroendocrine tumor, which is classified into limited and …